Last year, the Food and Drug Administration approved two new immunotherapies to treat certain leukemias and lymphomas. Now, in a study published in the New England Journal of Medicine, researchers detail who is most likely to benefit from the treatments, called CAR T cell therapy.
CAR T cell therapy trains the body’s immune system to target and destroy cancer cells in the blood; scientists take people’s own immune cells (T cells) and genetically engineer them to seek out and destroy cancer cells. The immune system can then attack cancer cells in the same way it does bacteria and viruses, and the therapy can lead to remissions from blood cancers of up to 80%.

But Dr. Jae Park, lead author of the research, says that many of those studies only follow people for a year or so, since CAR T cell therapy is still so new. Park, an assistant attending physician at Memorial Sloan Kettering Cancer Center, studied 53 people with acute lymphoblastic leukemia for up to five and a half years after they received CAR T therapy.

Before getting the one-time infusion of genetically engineered T cells, doctors generally use chemotherapy to eliminate as much cancer as possible. All of the people in the study had received several rounds of chemotherapy but their cancer returned. Park and his colleagues found that people who had the least amount of disease before receiving the CAR T therapy had the longest median survival overall and also experienced the fewest side effects from the tre…

Source: TIME: HealthCategory: Consumer Health News Authors: Tags: Uncategorized Cancer cancer cells cancer immunotherapy CAR T car t cell therapy car t gene therapy car t therapy cure for cancer healthytime leukemia leukemia treatments Source Type: news

Related Links:

CONCLUSION
Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but…

Source: Innovations in Clinical NeuroscienceCategory: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research

Publication date: Available online 31 January 2018 Source:The Lancet Author(s): Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman Background In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of …

Source: The LancetCategory: General Medicine Source Type: research

BOSTON (CBS) — The Dana Farber Cancer Institute and Boston Children’s Hospital will work to fight cancer in a new way thanks to a new treatment approved by the FDA.
CAR-T therapy is for kids and young adults with relapsed and refractory acute lymphoblastic leukemia (ALL).
“It’s really an entirely new type of therapy, an entirely new way to fight cancer,” said Dr. Lewis Silverman, the Clinical Director of the Pediatric Hematologic Malignancies Center.
Chemotherapy drugs attack dividing cells but are not specific to cancer cells, unlike this new treatment, according to Silverman.
“It&…

ConclusionsADORA2A rs2298383 and high cumulative dose of systemic MTX administration were significantly associated with MTX‐related leukoencephalopathy. Our results indicate that pharmacological intervention within the adenosine pathway may be both a treatment and preventative option for MTX‐related leukoencephalopathy.

Source: Pediatric Blood and CancerCategory: Cancer & Oncology Authors: Tags: Research Article Source Type: research

ConclusionsADORA2A rs2298383 and high cumulative dose of systemic MTX administration were significantly associated with MTX‐related leukoencephalopathy. Our results indicate that pharmacological intervention within the adenosine pathway may be both a treatment and preventative option for MTX‐related leukoencephalopathy.

Source: Pediatric Blood and CancerCategory: Cancer & Oncology Authors: Tags: Research Article Source Type: research

Discussion
Cancer occurs in all ages including children. Fortunately cancer is much less common in the pediatric age group accounting for

Source: PediatricEducation.orgCategory: Pediatrics Authors: Tags: Uncategorized Source Type: news

Abstract
Over 70,000 adolescent and young adults (AYA) aged 15 to 39 years are diagnosed with cancer each year in the US. The National Cancer Institute (NCI) has identified AYA cancer patients as a unique population. The most common cancers in this age group include tumors typically seen in pediatric patients such as acute lymphoblastic leukemia (ALL) and brain tumors, as well as cancers more typically seen in adult patients such as breast cancer and melanoma. In addition, some cancers have their highest incidence in AYA patients, such as Hodgkin Lymphoma, testicular cancer, and bone tumors. AYA patients face…

Abstract
Constitutional mismatch repair deficiency (CMMRD) syndrome is one of the rare diseases associated with a high risk of cancer. Causative mutations are found in DNA mismatch repair genes PMS2, MSH6, MSH2 or MLH1 that are well known in the context of Lynch syndrome. CMMRD follows an autosomal recessive inheritance trait and is characterized by childhood brain tumors and hematological malignancies as well as gastrointestinal cancer in the second and third decades of life. There is a high risk of multiple cancers, occurring synchronously and metachronously. In general, the prognosis is poor. About one third of…

Worldwide, cancer has superseded infection and heart disease as the leading cause of death. Generally viewed as a lesser public health priority in lower to middle income countries (LMIC), 60% of the children worldwide have limited access to effective cancer diagnosis, therapy and supportive care measures. As a result, relapse and treatment related toxicities with fatal outcomes contribute significantly to decreased survival rates compared to developed countries. Survival rates as low as 5% have been previously been reported in Vietnam. These reports utilized surveys based on face-to-face interviews that extrapolated incide…

Source: Cancer Epidemiology Biomarkers and PreventionCategory: Cancer & Oncology Authors: Tags: Healthcare Systems: Poster Presentations – Proffered Abstracts Source Type: research

Abstract
Cancer treatment can impact the hypothalamic-pituitary region of the developing brain, impairing appetite regulation and causing food craving in children who have survived cancer. We assessed food craving using a modified Food Craving Inventory in 22 survivors of pediatric acute lymphoblastic leukemia (ALL) and lymphoma (median age = 11.7 years) and evaluated its association with treatment exposure and changes in weight status over a one-year period. Mean total craving score was 2.1 (SD=0.7). Survivors reported significantly higher mean craving score for fast-foods [2.6 (SD=0.9)] than for sweets [2.1 (SD=…

Source: AppetiteCategory: Nutrition Authors: Tags: Appetite Source Type: research





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image